Literature DB >> 34137915

High postoperative neutrophil-lymphocyte ratio and low preoperative lymphocyte-monocyte ratio predict poor prognosis in gastric cancer patients receiving gastrectomy with positive lavage cytology: a retrospective cohort study.

Sho Sato1, Chikara Kunisaki2, Masazumi Takahashi3, Hirokazu Kubo1, Nobuhiro Tsuchiya1, Kei Sato1, Hiroshi Miyamoto1, Yuko Tamura3, Hiroki Kondo3, Yusaku Tanaka3, Kohei Kasahara4, Takashi Kosaka4, Hirotoshi Akiyama4, Yusuke Saigusa5, Itaru Endo4.   

Abstract

BACKGROUND: Long-term outcomes in gastric cancer patients with positive lavage cytology (CY1) are generally poor. This multi-institutional retrospective cohort study aims to evaluate the clinical significance of the neutrophil-lymphocyte ratio (NLR) and the lymphocyte-monocyte ratio (LMR) in CY1 gastric cancer patients.
METHODS: A total of 121 CY1 gastric cancer patients without other non-curative factors, who underwent macroscopically curative resection, were enrolled in this study. The cutoff values of preoperative NLR (pre-NLR), postoperative NLR (post-NLR), preoperative LMR (pre-LMR), and postoperative LMR (post-LMR) were defined by the Contal and O'Quigley method as 2.3, 3.0, 2.5, and 3.2, respectively. A Cox proportional hazard model was used to identify the independent prognostic factors among NLR, LMR, and other clinicopathological factors.
RESULTS: There were significant differences in the overall survival (OS) between the two groups: high post-NLR groups vs. low post-NLR group (median survival time, months) (10.9 vs. 22.8, P = 0.006) and high pre-LMR group vs. low pre-LMR group (21.3 vs. 11.0, P = 0.001). The LMR value elevated significantly after gastrectomy (P = 0.020), although not in the NLR value (P = 0.733). On multivariate analysis, high post-NLR (hazard ratio = 1.506; 95% confidence interval = 1.047-2.167; P = 0.027), low pre-LMR (1.773; 1.135-2.769, 0.012), and no postoperative chemotherapy (1.558; 1.053-2.305, 0.027) were found to be independent prognostic factors for adverse OS.
CONCLUSIONS: Because a combination of high post-NLR and low pre-LMR may be an adverse prognostic marker in resectable CY1 gastric cancer patients, it is necessary to conduct a prospective trial to confirm a useful perioperative chemotherapeutic regimen for these patients.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Lymphocytes; Monocytes; Neutrophils; Peritoneal lavage; Peritoneal neoplasms; Stomach neoplasms

Mesh:

Year:  2021        PMID: 34137915     DOI: 10.1007/s00423-021-02233-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  41 in total

1.  Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study.

Authors:  Yasuhiro Kodera; Seiji Ito; Yoshinari Mochizuki; Norifumi Ohashi; Chie Tanaka; Daisuke Kobayashi; Hiroshi Kojima; Takanori Matsui; Ken Kondo; Michitaka Fujiwara
Journal:  Gastric Cancer       Date:  2012-04-21       Impact factor: 7.370

2.  When is curative gastrectomy justified for gastric cancer with positive peritoneal lavage cytology but negative macroscopic peritoneal implant?

Authors:  Isao Miyashiro; Ko Takachi; Yuichiro Doki; Osamu Ishikawa; Hiroaki Ohigashi; Kohei Murata; Yo Sasaki; Shingi Imaoka; Akihiko Nakaizumi; Akemi Takenaka; Hiroshi Furukawa; Masahiro Hiratsuka
Journal:  World J Surg       Date:  2005-09       Impact factor: 3.352

3.  Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer.

Authors:  J J Bonenkamp; I Songun; J Hermans; C J van de Velde
Journal:  Br J Surg       Date:  1996-05       Impact factor: 6.939

4.  Prognostic significance of systemic neutrophil and leukocyte alterations in surgically treated endometrial cancer patients: a monoinstitutional study.

Authors:  Ryoko Takahashi; Seiji Mabuchi; Mahiru Kawano; Tomoyuki Sasano; Yuri Matsumoto; Hiromasa Kuroda; Takeshi Hisamatsu; Katsumi Kozasa; Kenjiro Sawada; Toshimitsu Hamasaki; Tadashi Kimura
Journal:  Gynecol Oncol       Date:  2015-02-11       Impact factor: 5.482

5.  High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer.

Authors:  Hideaki Shimada; Nobuhiro Takiguchi; Osamu Kainuma; Hiroaki Soda; Atsushi Ikeda; Akihiro Cho; Akinari Miyazaki; Hisashi Gunji; Hiroshi Yamamoto; Matsuo Nagata
Journal:  Gastric Cancer       Date:  2010-09-05       Impact factor: 7.370

6.  A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study).

Authors:  Y Kodera; S Ito; Y Mochizuki; K Kondo; K Koshikawa; N Suzuki; H Kojima; T Kojima; T Matsui; T Takase; K Tsuboi; M Fujiwara; A Nakao
Journal:  Eur J Surg Oncol       Date:  2009-03-27       Impact factor: 4.424

Review 7.  Global Cancer Incidence and Mortality Rates and Trends--An Update.

Authors:  Lindsey A Torre; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-14       Impact factor: 4.254

8.  The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer.

Authors:  M Stotz; M Pichler; G Absenger; J Szkandera; F Arminger; R Schaberl-Moser; H Samonigg; T Stojakovic; A Gerger
Journal:  Br J Cancer       Date:  2013-12-19       Impact factor: 7.640

9.  Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Zhi-Ming Li; Jia-Jia Huang; Yi Xia; Jian Sun; Ying Huang; Yu Wang; Ying-Jie Zhu; Ya-Jun Li; Wei Zhao; Wen-Xiao Wei; Tong-Yu Lin; Hui-Qiang Huang; Wen-Qi Jiang
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

10.  Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy.

Authors:  Li Chen; Ying Hao; Lihua Zhu; Sen Li; Yanjiao Zuo; Yuxin Zhang; Hongjiang Song; Yingwei Xue
Journal:  Onco Targets Ther       Date:  2017-08-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.